What is Unjha Formulations Ltd (531762) share price return in the past 10 years?

Unjha Formulations Ltd share price has appreciated 9.8% annually (CAGR) over the past ten years.

What is the share price of Unjha Formulations Ltd (531762)?

Company share prices are keep on changing according to the market conditions. The current trading price of Unjha Formulations Ltd (531762) on 10-Jun-2026 12:16:00 at 12:16 is 19.89.

What is the P/E ratio of Unjha Formulations?

The latest standalone P/E ratio of Unjha Formulations as of 10-Jun-2026 is 12.68.

What is the P/B ratio of Unjha Formulations Ltd (531762)?

The latest standalone P/B ratio of Unjha Formulations Ltd (531762) as of 10-Jun-2026 is 1.91.

What is the 52-week high and low of Unjha Formulations Ltd (531762)?

The 52-week high of Unjha Formulations Ltd (531762) is Rs. 30.40 and the 52-week low is Rs. 18.51.

Unjha Formulations Ltd (531762) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Unjha Formulations Ltd (531762)
Brand: Unjha Formulations

Unjha Formulations Ltd (531762)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 531762 NSE: Pharmaceuticals & Drugs | Small Cap | Unjha Formulations Share Price

Unjha Formulations Ltd (531762)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 531762 NSE: Pharmaceuticals & Drugs | Small Cap | Unjha Formulations Share Price

Key Metrics

Valuation Multiples

Market Cap

₹9 Cr.

Current Price

₹19.9

52-Week Low / High

₹19 / 30

TTM EPS

₹1.6

TTM Sales

₹15.6 Cr.

Book Value per Share

₹10.4

P/E Ratio

12.68

Lower than its 5-year historical median

Industry PE

Price to Book (P/B)

1.91

Lower than its 5-year historical median

Price to Sales (P/S)

0.57

Higher than its 5-year historical median

EV/EBITDA

6.61

Lower than its 5-year historical median

Dividend Yield

0.00%

Profitability Efficiency

Return on Equity (ROE)

13.88%

Outperforms industry median

Return on Capital Employed (ROCE)

18.11%

Outperforms industry median

Return on Assets (ROA)

8.59%

Operating Profit Margin

3.7%

Net Profit Margin

2.94%

Gross Profit Margin

4.5%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Slowing versus 3-year growth rate

-25.08%

Operating Profit Growth (1 Year)

Slowing versus 3-year growth rate

-13.79%

Net Profit Growth (1 Year)

Improving versus 3-year growth rate

46.43%

Asset Quality

Promoter Holding

36.92%

Pledged shares (%) of Promoter's holding (%)

0.00%

Reserves

Equity

₹4.5 Cr.

Face Value

₹10

All Time Low / High

₹1.00 / 39.00

Unjha Formulations stock performance

Key Ratios

Check Before You Invest

M-Cap below 100cr DeciZen not available

Q.1 Is Unjha Formulations Ltd a good quality company?

Unjha Formulations Ltd is a quality company, based on a multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

How does Unjha Formulations Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Unjha Formulations Ltd vs industry peers?

Unjha Formulations Ltd revenue CAGR is 5.51%, compared to the industry median CAGR of 5.35%, indicating stable growth and maintaining its market share.

Q.1 Promoter shareholding and pledge status of Unjha Formulations Ltd?

Promoters hold 36.92% of the Unjha Formulations Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Stock return of Unjha Formulations Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of 8.1% based on the current price.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	73.7%	67.6%	32.2%	25.4%	25.6%	26.8%	21.1%	16.8%	19.5%	18.1%	-
Value Creation Index ⓘ	4.3	3.8	1.3	0.8	0.8	0.9	0.5	0.2	0.4	0.3	-
Growth Parameters ⓘ
Sales ⓘ	10.4	12.2	11.3	11.4	10.6	10	14.2	13.2	18.5	13.9	16
Sales YoY Gr.	-	18%	-7.7%	1.1%	-7.2%	-6%	42.2%	-7.1%	40.7%	-25.1%	-
Adj EPS ⓘ	0.6	0.7	0.6	0.7	0.7	-0	0.3	0.6	0.6	0.9	1.6
YoY Gr.	-	15.8%	-10.6%	13.6%	1.5%	-104.4%	NA	87.5%	3.3%	50%	-
BVPS (₹) ⓘ	0.9	1.6	2.2	3.4	4.1	4.3	4.9	5.5	6.1	7	10.4
Adj Net Profit ⓘ	0.3	0.3	0.3	0.3	0.3	-0	0.1	0.3	0.3	0.4	1
Cash Flow from Ops. ⓘ	0.4	0.4	0.1	-0.1	0.4	-0.7	0.3	-0.3	1	-0	-
Debt/CF from Ops. ⓘ	0	0.1	0	0	0	0	0	0	0	0	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	3.3%	5.5%	-0.7%	-25.1%
Adj EPS ⓘ	5.6%	6.5%	42.7%	50%
BVPSⓘ	25.2%	11.6%	13.1%	14.9%
Share Price	9.8%	15%	19.6%	-15.8%

Key Financial Parameters ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	49.5	37.1	24.4	22	18.4	-0.8	7	11.6	10.7	14.2	18
Op. Profit Mgn % ⓘ	3.5	3.1	3	2.6	2.3	3.7	2.3	3.3	3.1	3.7	7.1
Net Profit Mgn % ⓘ	2.5	2.4	2.3	2.6	2.9	-0.2	1	2	1.5	3	4.5
Debt to Equity ⓘ	0	0.1	0	0	0	0	0	0	0	0	0
Working Cap Days ⓘ	57	51	65	63	61	71	54	59	52	74	56
Cash Conv. Cycle ⓘ	-40	-29	-36	-26	-13	2	13	23	19	26	34

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	10.37	12.24	11.30	11.42	10.60	9.96	14.16	13.15	18.50	13.86
Operating Expenses ⓘ +	10	11.86	10.95	11.12	10.35	9.59	13.84	12.72	17.92	13.36
Manufacturing Costs	1.36	1.82	1.54	1.90	1.94	1.86	2.27	1.03	1.20	0.53
Material Costs	7.67	9.11	8.51	7.83	7.36	6.73	10.48	10.45	15.28	11.17
Employee Cost	0.26	0.30	0.35	0.42	0.44	0.37	0.46	0.51	0.59	0.62
Other Costs ⓘ	0.71	0.64	0.56	0.97	0.61	0.63	0.63	0.72	0.85	1.03
Operating Profit ⓘ	0.36	0.38	0.34	0.30	0.25	0.36	0.32	0.43	0.58	0.50
Operating Profit Margin (%)	3.5%	3.1%	3.0%	2.6%	2.3%	3.7%	2.3%	3.3%	3.1%	3.6%
Other Income ⓘ +	0.08	0.11	0.04	0.10	0.26	0.22	0.19	0.03	0.01	0.13
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Interest ⓘ	0.10	0.10	0.02	0.01	0.12	0.17	0.13	0.06	0.05	0.01
Depreciation ⓘ	0.08	0.09	0.10	0.09	0.08	0.08	0.08	0.08	0.08	0.10
Profit Before Tax ⓘ	0.26	0.30	0.26	0.30	0.31	0.33	0.30	0.33	0.45	0.52
Tax ⓘ	0	0	0	0	0	0.23	0.05	0.05	0.17	0.12
Profit After Tax	0.26	0.30	0.26	0.30	0.31	0.10	0.25	0.28	0.28	0.41
PAT Margin (%)	2.5%	2.4%	2.3%	2.6%	2.9%	1.0%	1.8%	2.2%	1.5%	2.9%
Adjusted EPS (₹)	0.6	0.7	0.6	0.7	0.7	0.2	0.6	0.6	0.6	0.9
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Valuation of Unjha Formulations - Standalone

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	0.65	0.94	1.21	1.51	1.81	1.92	2.17	2.45	2.73	3.14
Share Capital ⓘ	4.48	4.48	4.48	4.48	4.48	4.48	4.48	4.48	4.48	4.48
Reserves ⓘ	-3.83	-3.54	-3.27	-2.97	-2.67	-2.56	-2.31	-2.03	-1.75	-1.34
Debt +	0	0.05	0	0	0	0	0	0	0	0
Long Term Debt	0	0.05	0	0	0	0	0	0	0	0
Short Term Debt	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	2.28	2.79	2.75	2.10	1.86	1.60	1.25	0.94	2.04	1.17
Others Liabilities ⓘ	0	-0	0	0.05	0.04	0.01	0.04	0.02	0.16	0.25
Total Liabilities ⓘ	2.93	3.78	3.96	3.65	3.72	3.53	3.45	3.41	4.93	4.56
Fixed Assets
Net Fixed Assets ⓘ +	1.03	1.22	1.16	1.12	1.14	1.12	1.07	1.10	1.12	1.20
Gross Block	3.70	3.98	4.02	4.06	4.16	4.23	4.25	4.35	4.46	4.63
Accumulated Depreciation	2.67	2.76	2.86	2.94	3.02	3.10	3.18	3.26	3.34	3.43
CWIP ⓘ	0	0	0	0	0	0	0	0	0	0
Investments ⓘ	0	0	0	0	0	0	0	0	0	0
Inventories	0.55	1.16	1.02	0.55	0.48	1.15	1.07	1.14	1.26	1.03
Trade Receivables	0.81	0.65	0.78	1.34	1.15	0.98	0.70	1.05	1.61	1.51
Cash Equivalents	0.19	0.34	0.49	0.65	0.94	0.17	0.43	0.01	0.87	0.64
Others Assets ⓘ	0.35	0.40	0.51	-0	0	0.11	0.19	0.12	0.07	0.17
Total Assets ⓘ	2.93	3.78	3.96	3.65	3.72	3.53	3.45	3.41	4.93	4.56

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	0.41	0.39	0.14	-0.12	0.39	-0.70	0.28	-0.26	1.03	-0.04
PBT ⓘ	0.26	0.30	0.26	0.30	0.31	0.10	0.25	0.33	0.45	0.52
Adjustment ⓘ	0.19	0.19	0.12	0.10	0.20	0.25	0.21	0.13	0.13	0.07
Changes in Working Capital ⓘ	0.07	0	-0.23	-0.51	0.01	-0.89	-0.05	-0.67	0.49	-0.5
Tax Paid ⓘ	0	0	0	0	0	0	0	-0.05	-0.05	-0.14
Cash Flow From Investing Activity ⓘ +	-0.02	-0.28	0.06	0.04	-0.10	-0.06	-0.02	-0.10	-0.11	-0.18
Capex	-0.02	-0.28	0.06	0.04	-0.10	-0.06	-0.02	-0.10	-0.11	-0.18
Net Investments	0	0	0	0	0	0	0	0	0	0
Others ⓘ	0	0	0	0	0	0	0	0	0	0
Cash Flow From Financing Activity ⓘ +	-0.40	0.05	-0.05	0.23	0	0	0	-0.06	-0.05	-0.01
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	0.05	-0.05	0	0	0	0	0	0	0
Interest Paid ⓘ	0	0	0	0	0	0	0	-0.06	-0.05	-0.01
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	-0.40	0	0	0.23	0	0	0	0	0	0
Net Cash Flow ⓘ	-0.01	0.15	0.15	0.16	0.29	-0.77	0.26	-0.42	0.86	-0.23

Financial Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	89.75	52.48	31.18	24.22	18.57	5.55	12.35	12.22	10.72	13.88
ROCE (%)	73.7	67.61	32.15	25.41	25.57	26.8	21.13	16.76	19.53	18.11
Asset Turnover Ratio	3.33	3.65	2.92	3	2.88	2.75	4.06	3.83	4.43	2.92
PAT to CFO Conversion(x)	1.58	1.3	0.54	-0.4	1.26	-7	1.12	-0.93	3.68	-0.1
Working Capital Days
Receivable Days	26.10	21.70	23	33.80	42.90	39	21.50	24.20	26.20	41
Inventory Days	22.50	25.50	35.30	25.10	17.80	29.90	28.60	30.60	23.60	30.20
Payable Days	113.90	101.50	118.80	113	98.20	93.90	49.50	38.20	35.60	52.40

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Unjha Formulations Ltd FAQs

The current trading price of Unjha Formulations on 10-Jun-2026 12:16 is ₹19.89.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 09-Jun-2026 the market cap of Unjha Formulations stood at ₹8.94 Cr

The latest P/E ratio of Unjha Formulations as of 09-Jun-2026 is 12.68.

The latest P/B ratio of Unjha Formulations as of 09-Jun-2026 is 1.91.

The 52-week high of Unjha Formulations is ₹30.40 and the 52-week low is ₹18.51.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Unjha Formulations is ₹15.59 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Unjha Formulations Ltd is a good quality company.

The key valuation ratios of Unjha Formulations Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Unjha Formulations Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

About Unjha Formulations Ltd

Unjha Formulations (U-For), incorporated in 1987, is the sister concern of Urvesh Psyllium Industries Limited. U-For is the pharmaceuticals manufacturing unit, which is going to various category of formulation like tablet, capsule, oral liquids, injectables (SVP) and powder section to manufacture ayurvedic as well as allopathy products.

Fibron Powder & Fibron Sugar Free Powder are the branded ayurvedic products of the company, based on psyllium husk. The products met with an overwhelming success in our domestic market. The products mainly caters to somewhat sophisticated market segment who is conscious about their health and at the same time are very particular about various flavour like Orange, Lemon, Lime & Mango taste of the product.

Fibron Powder & Fibron SF powder offer excellent value for the money. Speed U - for could able to promote Fibron Powder & Fibron Powder SF at a most competitive price without sacrificing on quality mainly because their sister concern unit Urvesh Psyllium Industries Ltd. is one of the largest raw material supplier and processor of plyllium in the world. It may be important to note here that even Glaxo India Ltd, Proctor & Gamble, Nicholas Piramal India Ltd are the company's most valued costumers.

The company has entered into an agreement with Nicholas Piramal India for sale of Isabgol Husk based product `Tybogel` and Morepen Laboratories for sale of Dr.Mopren Sat Isabgol.

Urvesh Psyllium Industries Limited is the leading processor and exporter of Psyllium Husk & Powder in India.The company is in this line of business since last 52 years (i.e. from 1949). Initially it processed and supplied Psyllium products in local market but, looking to the worldwide demand, in 1966 it started to export Psyllium Products in the name of Rajendra Brothers. Later on with the increase of demand from overseas buyers there rose a need to expand the business, and thus Urvesh Psyllium Industries was formed in 1985, which later on was converted into a Limited Company in the year 1995.

Product range of the company includes:

Fibron Powder
Fibron Sugar Free Powder
Psyllium Capsules

Achievements/ recognition:

GMP & ISO:9001-2000 certified unit.

Unjha Formulations Ltd (531762)

Unjha Formulations Ltd (531762)

Unjha Formulations stock performance

Check Before You Invest

M-Cap below 100cr DeciZen not available

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Unjha Formulations - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Unjha Formulations Ltd FAQs

About Unjha Formulations Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Unjha Formulations Ltd (531762)

Unjha Formulations Ltd (531762)

Unjha Formulations stock performance

Check Before You Invest

M-Cap below 100cr DeciZen not available

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Unjha Formulations - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Unjha Formulations Ltd FAQs

What is the share price of Unjha Formulations?

What is the market cap of Unjha Formulations?

What is the P/E ratio of Unjha Formulations?

What is the P/B ratio of Unjha Formulations?

What is the 52-week high and low of Unjha Formulations?

What is the TTM revenue of Unjha Formulations?

Is Unjha Formulations Ltd a good quality company?

Is Unjha Formulations Ltd undervalued or overvalued?

Is Unjha Formulations Ltd a good buy now?

About Unjha Formulations Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.